JP2002510652A5 - - Google Patents

Download PDF

Info

Publication number
JP2002510652A5
JP2002510652A5 JP2000542041A JP2000542041A JP2002510652A5 JP 2002510652 A5 JP2002510652 A5 JP 2002510652A5 JP 2000542041 A JP2000542041 A JP 2000542041A JP 2000542041 A JP2000542041 A JP 2000542041A JP 2002510652 A5 JP2002510652 A5 JP 2002510652A5
Authority
JP
Japan
Prior art keywords
intravascular
preferred
present
formulations
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000542041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002510652A (ja
JP4664499B2 (ja
Filing date
Publication date
Priority claimed from US09/057,143 external-priority patent/US6136799A/en
Application filed filed Critical
Publication of JP2002510652A publication Critical patent/JP2002510652A/ja
Publication of JP2002510652A5 publication Critical patent/JP2002510652A5/ja
Application granted granted Critical
Publication of JP4664499B2 publication Critical patent/JP4664499B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000542041A 1998-04-08 1999-03-22 共溶媒処方物 Expired - Lifetime JP4664499B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/057,143 US6136799A (en) 1998-04-08 1998-04-08 Cosolvent formulations
US09/057,143 1998-04-08
PCT/US1999/006196 WO1999051271A2 (en) 1998-04-08 1999-03-22 Compositions comprising glycol derivatives and alcohols

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010207684A Division JP5548079B2 (ja) 1998-04-08 2010-09-16 共溶媒処方物

Publications (3)

Publication Number Publication Date
JP2002510652A JP2002510652A (ja) 2002-04-09
JP2002510652A5 true JP2002510652A5 (enExample) 2010-11-18
JP4664499B2 JP4664499B2 (ja) 2011-04-06

Family

ID=22008769

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000542041A Expired - Lifetime JP4664499B2 (ja) 1998-04-08 1999-03-22 共溶媒処方物
JP2010207684A Expired - Lifetime JP5548079B2 (ja) 1998-04-08 2010-09-16 共溶媒処方物
JP2014016658A Expired - Lifetime JP5887368B2 (ja) 1998-04-08 2014-01-31 共溶媒処方物
JP2015204318A Pending JP2016053046A (ja) 1998-04-08 2015-10-16 共溶媒処方物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010207684A Expired - Lifetime JP5548079B2 (ja) 1998-04-08 2010-09-16 共溶媒処方物
JP2014016658A Expired - Lifetime JP5887368B2 (ja) 1998-04-08 2014-01-31 共溶媒処方物
JP2015204318A Pending JP2016053046A (ja) 1998-04-08 2015-10-16 共溶媒処方物

Country Status (11)

Country Link
US (2) US6136799A (enExample)
EP (1) EP1073467B1 (enExample)
JP (4) JP4664499B2 (enExample)
AT (1) ATE275974T1 (enExample)
AU (1) AU758989B2 (enExample)
CA (1) CA2326198C (enExample)
DE (1) DE69920201T2 (enExample)
DK (1) DK1073467T3 (enExample)
ES (1) ES2229693T3 (enExample)
PT (1) PT1073467E (enExample)
WO (1) WO1999051271A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586661B1 (en) 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
EP1368467B1 (en) * 2000-11-07 2007-04-25 North Carolina State University Putrescine-n-methyltransferase promoter
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
EP1476201B1 (en) 2002-02-19 2008-12-24 Resolution Chemicals Limited Solvent-based sterilisation of steroids
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
CN101223135A (zh) * 2005-07-18 2008-07-16 特瓦制药工业有限公司 帕立骨化醇的制备
US20070166187A1 (en) * 2006-01-18 2007-07-19 Song Jing F Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
CA2651283A1 (en) * 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
US20100075933A1 (en) * 2008-07-28 2010-03-25 Sunita Vijay Shelke Injectable compositions of vitamin d compounds
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
EP2545940A1 (de) * 2011-07-14 2013-01-16 hameln rds gmbh Parenterale Zusammensetzungen
MY172886A (en) 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
ES2698403T3 (es) * 2012-12-27 2019-02-04 Pharmathen Sa Composición farmacéutica inyectable estable de agonista de receptor de vitamina D y proceso para su preparación
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
CN106265492B (zh) * 2015-06-04 2020-12-11 成都国为生物医药有限公司 一种含有帕立骨化醇的药物组合物及其制备方法
WO2018044468A1 (en) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198391A (en) * 1973-07-20 1980-04-15 R. P. Scherer Ltd. Pharmaceutical compositions
US4212886A (en) * 1978-11-01 1980-07-15 Survival Technology, Inc. Stabilized benactyzine hydrochloride
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
DE3316510A1 (de) * 1983-05-06 1984-11-08 Bayer Ag Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
US4588528A (en) * 1984-05-31 1986-05-13 Wisconsin Alumni Research Foundation 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
US4594340A (en) * 1984-11-29 1986-06-10 Hoffmann-La Roche Inc. 25,26-dehydro-1α,24R-dihydroxycholecalciferol and 25,26-dehydro-1α,24S-dihydroxycholecalciferol and the epimeric mixture
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
DK191889D0 (da) * 1989-04-20 1989-04-20 Bukh Meditec Kosmetisk middel
AU649057B2 (en) * 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
US5502224A (en) * 1991-06-04 1996-03-26 Marigen, S.A. Biotenside esters and phosphatides with vitamin-D and vitamin-E compounds
FR2677884B1 (fr) * 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
AU667675B2 (en) * 1991-06-28 1996-04-04 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
GB9201920D0 (en) * 1992-01-29 1992-03-18 Leo Pharm Prod Ltd Novel treatment i
JPH05246891A (ja) * 1992-03-09 1993-09-24 Kobayashi Seiyaku Kogyo Kk 安定な抗膵炎用注射液
KR960013798B1 (ko) * 1992-04-24 1996-10-10 재단법인 한국전자통신연구소 평면 도파로형 공간 스위치
AU5861396A (en) * 1995-05-19 1996-11-29 Abbott Laboratories Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administration
US5597815A (en) * 1995-07-13 1997-01-28 Wisconsin Alumni Research Foundation Prevention of hyperphosphatemia in kidney disorder patients
AU2588297A (en) * 1996-04-04 1997-10-29 Ortho Pharmaceutical Corporation Liposome-based topical vitamin d formulation
DE69804169T2 (de) * 1997-06-27 2002-08-29 Akzo Nobel N.V., Arnheim/Arnhem Oral anzuwendende flüssige Arzneilösung
CA2211949A1 (en) * 1997-07-21 1999-01-29 David Farley Johnson Nonaqueous compositions for parenteral administration
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations

Similar Documents

Publication Publication Date Title
CN1125653C (zh) 含有伏利康唑的药物制剂
KR102699155B1 (ko) 단트롤렌을 포함하는 수성 조성물
CA2066731A1 (en) Liquid oral pharmaceutical compositions having anti-inflammatory activity
JP2004529934A5 (enExample)
BR112012033077B1 (pt) composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
CZ25793A3 (en) Pharmaceutical mixtures of phlorphenicol
BRPI0709617A2 (pt) composição farmacêutica, e, métodos para tratar elevações agudas de pressão sangüìnea em um indivìduo humano, para induzir a hipotensão em um indivìduo humano, e para produzir uma composição farmacêutica para administração intravenosa
JP6349057B2 (ja) オロパタジン含有水性組成物
ES2359856T3 (es) Formulación parenteral estable que contiene un inhibidor de vsr de una estructura de benzodiazepina.
ES2336034T3 (es) Composiciones de diclofenaco inyectables estables.
WO2002102383A1 (fr) Preparation de cilostazol aqueuse pour injections
JP7374501B2 (ja) メロキシカム組成物、製剤及びその製造方法と応用
JP2012167132A (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤
JP6818019B2 (ja) レファムリンの注射可能医薬組成物
JP5113323B2 (ja) ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物
WO2014013903A1 (ja) タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
WO2021090183A1 (en) Liquid melphalan composition
WO2019097413A1 (en) Stable non-aqueous pharmaceutical compositions
WO2009150278A1 (es) Una composición farmacéutica de melfalano
JP2007514778A5 (enExample)
JP5205909B2 (ja) 粘膜適用液剤
JPH05139955A (ja) 安定な点眼剤
CN101677943B (zh) 使用苯甲醇的多剂量浓缩艾司洛尔
EP0236280B1 (en) Injectable pharmaceutical formulations of active principles having general anaesthetic activity
CN100467024C (zh) 氯诺昔康注射用组合物及其制备方法